The Transcription Factor HOXA5: Novel Insights into Metabolic Diseases and Adipose Tissue Dysfunction
Authors:
- Luca ParrilloLPLuca Parrillo
- Rosa SpinelliRSRosa Spinelli
- Michele LongoMichele Longo
- Federica ZatteraleFZFederica Zatterale
- Gianluca SantamariaGSGianluca Santamaria
- Alessia LeoneALAlessia Leone
- Michele CampitelliMCMichele Campitelli
- Gregory Alexander RacitiGRGregory Alexander Raciti
- Francesco BeguinotFBFrancesco Beguinot
Open Access
Abstract
The transcription factor HOXA5, from the HOX gene family, has long been studied due to its critical role in physiological activities in normal cells, such as organ development and body patterning, and pathological activities in cancer cells. Nonetheless, recent evidence supports the hypothesis of a role for HOXA5 in metabolic diseases, particularly in obesity and type 2 diabetes (T2D). In line with the current opinion that adipocyte and adipose tissue (AT) dysfunction belong to the group of primary defects in obesity, linking this condition to an increased risk of insulin resistance (IR) and T2D, the HOXA5 gene has been shown to regulate adipocyte function and AT remodeling both in humans and mice. Epigenetics adds complexity to HOXA5 gene regulation in metabolic diseases. Indeed, epigenetic mechanisms, specifically DNA methylation, influence the dynamic HOXA5 expression profile. In human AT, the DNA methylation profile at the HOXA5 gene is associated with hypertrophic obesity and an increased risk of developing T2D. Thus, an inappropriate HOXA5 gene expression may be a mechanism causing or maintaining an impaired AT function in obesity and potentially linking obesity to its associated disorders. In this review, we integrate the current evidence about the involvement of HOXA5 in regulating AT function, as well as its association with the pathogenesis of obesity and T2D. We also summarize the current knowledge on the role of DNA methylation in controlling HOXA5 expression. Moreover, considering the susceptibility of epigenetic changes to reversal through targeted interventions, we discuss the potential therapeutic value of targeting HOXA5 DNA methylation changes in the treatment of metabolic diseases.Keywords
Funding Information
- Ministero dell’Università e della Ricerca (CUP E63C22000940007, CUP B83C22004880006, 2020N5WK98, 2017CPLH32, CUP E63C22001440001)
- Ministero della Salute (CUP E63C22000940007, CUP B83C22004880006, 2020N5WK98, 2017CPLH32, CUP E63C22001440001)
This publication has 100 references indexed in Scilit:
- Genetic Effects on DNA Methylation and Its Potential Relevance for Obesity in Mexican AmericansPLOS ONE, 2013
- MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5BMC Cancer, 2012
- Genetic Predisposition for Type 2 Diabetes, but Not for Overweight/Obesity, Is Associated with a Restricted AdipogenesisPLOS ONE, 2011
- Switch from Stress Response to Homeobox Transcription Factors in Adipose Tissue After Profound Fat LossPLOS ONE, 2010
- Adipocyte Apoptosis, a Link between Obesity, Insulin Resistance, and Hepatic SteatosisJournal of Biological Chemistry, 2010
- Epigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological featuresMolecular Carcinogenesis, 2009
- Inactivation of HOXA Genes by Hypermethylation in Myeloid and Lymphoid Malignancy is Frequent and Associated with Poor PrognosisClinical Cancer Research, 2007
- Impact of the Loss of Hoxa5 Function on Lung AlveogenesisThe American Journal of Pathology, 2006
- Evidence for a role of developmental genes in the origin of obesity and body fat distributionProceedings of the National Academy of Sciences, 2006
- Microarray profiling of isolated abdominal subcutaneous adipocytes from obese vs non-obese Pima Indians: increased expression of inflammation-related genesDiabetologia, 2005